Because the gene encoding protein p53 is often mutated in cancers, TRAIL's ability to activate apoptosis independently of the p53, together with its tumor-selectivity, made TRAIL an attractive therapeutic target (Elmore, 2007; Lim et al., 2019). Here, TP53 is linked to cancer.